


## KTX-951

<b>Cat. No.:</b>	HY-148290		
<b>CAS No.:</b>	2573298-36-7		
<b>Molecular Formula:</b>	C <sub>46</sub> H <sub>52</sub> F <sub>2</sub> N <sub>8</sub> O <sub>6</sub>		
<b>Molecular Weight:</b>	850.95		
<b>Target:</b>	IRAK; PROTACs		
<b>Pathway:</b>	Immunology/Inflammation; PROTAC		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (58.76 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.1752 mL	5.8758 mL	11.7516 mL
5 mM	0.2350 mL	1.1752 mL	2.3503 mL
10 mM	0.1175 mL	0.5876 mL	1.1752 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

KTX-951 is a PROTAC targeting IRAK4 degradation (DC<sub>50</sub>=18 nM). KTX-951 (10 mg/kg) shows the oral bioavailability (F%) of 22% in a rat model. KTX-951 has good anticancer potential<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IRAK4<sup>[1]</sup>.

### REFERENCES

[1]. Walker D H, et al. Degradors targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broader activity with durable and complete regressions in MYD88 mutant lymphoma xenografts in vivo. *Cancer Research*, 2020, 80(16\_Supplement): 5222-5222.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA